Medtronic Debt to Equity Ratio 2012-2025 | MDT
Current and historical debt to equity ratio values for Medtronic (MDT) over the last 10 years. The debt/equity ratio can be defined as a measure of a company's financial leverage calculated by dividing its long-term debt by stockholders' equity. Medtronic debt/equity for the three months ending October 31, 2025 was 0.57.
| Medtronic Debt/Equity Ratio Historical Data | |||
|---|---|---|---|
| Date | Long Term Debt | Shareholder's Equity | Debt to Equity Ratio |
| 2025-10-31 | $42.49B | $48.86B | 0.87 |
| 2025-07-31 | $42.84B | $48.13B | 0.89 |
| 2025-04-30 | $43.42B | $48.26B | 0.90 |
| 2025-01-31 | $40.36B | $49.62B | 0.81 |
| 2024-10-31 | $41.33B | $48.72B | 0.85 |
| 2024-07-31 | $41.59B | $48.16B | 0.86 |
| 2024-04-30 | $39.56B | $50.42B | 0.79 |
| 2024-01-31 | $38.84B | $52.00B | 0.75 |
| 2023-10-31 | $38.44B | $51.65B | 0.74 |
| 2023-07-31 | $39.41B | $51.37B | 0.77 |
| 2023-04-30 | $39.28B | $51.67B | 0.76 |
| 2023-01-31 | $42.52B | $51.62B | 0.82 |
| 2022-10-31 | $41.18B | $52.06B | 0.79 |
| 2022-07-31 | $37.07B | $52.84B | 0.70 |
| 2022-04-30 | $38.26B | $52.72B | 0.73 |
| 2022-01-31 | $39.09B | $52.71B | 0.74 |
| 2021-10-31 | $39.60B | $52.16B | 0.76 |
| 2021-07-31 | $40.14B | $51.66B | 0.78 |
| 2021-04-30 | $41.48B | $51.60B | 0.80 |
| 2021-01-31 | $46.34B | $50.93B | 0.91 |
| 2020-10-31 | $45.57B | $50.32B | 0.91 |
| 2020-07-31 | $43.46B | $50.44B | 0.86 |
| 2020-04-30 | $39.82B | $50.87B | 0.78 |
| 2020-01-31 | $40.87B | $51.95B | 0.79 |
| 2019-10-31 | $40.33B | $50.72B | 0.80 |
| 2019-07-31 | $40.77B | $50.50B | 0.81 |
| 2019-04-30 | $39.48B | $50.21B | 0.79 |
| 2019-01-31 | $38.79B | $49.94B | 0.78 |
| 2018-10-31 | $38.44B | $49.71B | 0.77 |
| 2018-07-31 | $39.39B | $50.33B | 0.78 |
| 2018-04-30 | $40.57B | $50.82B | 0.80 |
| 2018-01-31 | $45.46B | $50.34B | 0.90 |
| 2017-10-31 | $42.88B | $51.58B | 0.83 |
| 2017-07-31 | $49.46B | $50.79B | 0.97 |
| 2017-04-30 | $49.53B | $50.33B | 0.98 |
| 2017-01-31 | $48.09B | $49.49B | 0.97 |
| 2016-10-31 | $48.11B | $50.29B | 0.96 |
| 2016-07-31 | $47.71B | $50.89B | 0.94 |
| 2016-04-30 | $47.58B | $52.06B | 0.91 |
| 2016-01-31 | $51.89B | $50.82B | 1.02 |
| 2015-10-31 | $52.68B | $52.27B | 1.01 |
| 2015-07-31 | $51.82B | $52.81B | 0.98 |
| 2015-04-30 | $53.46B | $53.23B | 1.00 |
| 2015-01-31 | $35.06B | $20.17B | 1.74 |
| 2014-10-31 | $19.34B | $19.44B | 1.00 |
| 2014-07-31 | $18.31B | $19.25B | 0.95 |
| 2014-04-30 | $18.50B | $19.44B | 0.95 |
| 2014-01-31 | $17.88B | $19.35B | 0.92 |
| 2013-10-31 | $17.72B | $18.74B | 0.95 |
| 2013-07-31 | $16.45B | $18.52B | 0.89 |
| 2013-04-30 | $16.23B | $18.67B | 0.87 |
| 2013-01-31 | $17.11B | $17.84B | 0.96 |
| 2012-10-31 | $16.79B | $17.18B | 0.98 |
| 2012-07-31 | $16.00B | $17.26B | 0.93 |
| 2012-04-30 | $15.71B | $17.11B | 0.92 |
| 2012-01-31 | $14.74B | $17.17B | 0.86 |
| 2011-10-31 | $15.01B | $16.74B | 0.90 |
| 2011-07-31 | $14.75B | $16.34B | 0.90 |
| 2011-04-30 | $14.71B | $15.97B | 0.92 |
| 2011-01-31 | $15.24B | $15.36B | 0.99 |
| 2010-10-31 | $14.49B | $14.83B | 0.98 |
| 2010-07-31 | $14.06B | $14.60B | 0.96 |
| 2010-04-30 | $13.46B | $14.63B | 0.92 |
| 2010-01-31 | $10.85B | $14.32B | 0.76 |
| 2009-10-31 | $10.68B | $13.61B | 0.79 |
| 2009-07-31 | $10.43B | $13.14B | 0.79 |
| 2009-04-30 | $10.41B | $13.18B | 0.79 |
| 2009-01-31 | $9.70B | $13.06B | 0.74 |
| 2008-10-31 | $9.41B | $12.62B | 0.75 |
| 2008-07-31 | $10.49B | $12.24B | 0.86 |
| 2008-04-30 | $10.66B | $11.54B | 0.92 |
| 2008-01-31 | $10.45B | $10.97B | 0.95 |
| 2007-10-31 | $9.11B | $11.48B | 0.79 |
| 2007-07-31 | $8.52B | $11.14B | 0.76 |
| 2007-04-30 | $8.54B | $10.98B | 0.78 |
| 2007-01-31 | $8.59B | $10.98B | 0.78 |
| 2006-10-31 | $8.62B | $10.28B | 0.84 |
| 2006-07-31 | $10.29B | $9.90B | 1.04 |
| 2006-04-30 | $10.28B | $9.38B | 1.10 |
| 2006-01-31 | $6.60B | $11.74B | 0.56 |
| 2005-10-31 | $6.63B | $11.13B | 0.60 |
| 2005-07-31 | $6.34B | $10.58B | 0.60 |
| 2005-04-30 | $6.17B | $10.45B | 0.59 |
| 2005-01-31 | $5.46B | $10.23B | 0.53 |
| 2004-10-31 | $5.26B | $9.93B | 0.53 |
| 2004-07-31 | $5.11B | $9.45B | 0.54 |
| 2004-04-30 | $5.03B | $9.08B | 0.56 |
| 2004-01-31 | $4.75B | $8.69B | 0.55 |
| 2003-10-31 | $4.60B | $8.30B | 0.55 |
| 2003-07-31 | $4.45B | $8.18B | 0.54 |
| 2003-04-30 | $4.50B | $7.91B | 0.57 |
| 2003-01-31 | $4.34B | $7.57B | 0.57 |
| 2002-10-31 | $4.27B | $7.18B | 0.59 |
| 2002-07-31 | $4.46B | $6.73B | 0.66 |
| 2002-04-30 | $4.47B | $6.43B | 0.70 |
| 2002-01-31 | $3.98B | $6.16B | 0.65 |
| 2001-10-31 | $3.89B | $5.83B | 0.67 |
| 2001-07-31 | $1.50B | $5.77B | 0.26 |
| 2001-04-30 | $1.53B | $5.51B | 0.28 |
| 2001-01-31 | $1.15B | $5.36B | 0.22 |
| 2000-10-31 | $1.21B | $4.96B | 0.24 |
| 2000-07-31 | $1.15B | $4.74B | 0.24 |
| 2000-04-30 | $1.18B | $4.51B | 0.26 |
| 2000-01-31 | $1.30B | $4.12B | 0.32 |
| 1999-10-31 | $1.31B | $3.87B | 0.34 |
| 1999-07-31 | $1.19B | $3.81B | 0.31 |
| 1999-04-30 | $1.22B | $3.66B | 0.33 |
| 1999-01-31 | $1.34B | $3.58B | 0.37 |
| 1998-10-31 | $0.92B | $2.91B | 0.32 |
| 1998-07-31 | $0.72B | $2.07B | 0.35 |
| 1998-04-30 | $0.73B | $2.04B | 0.36 |
| 1998-01-31 | $0.77B | $1.89B | 0.41 |
| 1997-10-31 | $0.67B | $1.94B | 0.34 |
| 1997-07-31 | $0.68B | $1.84B | 0.37 |
| 1997-04-30 | $0.66B | $1.75B | 0.38 |
| 1997-01-31 | $0.66B | $2.03B | 0.33 |
| 1996-10-31 | $0.65B | $2.02B | 0.32 |
| 1996-07-31 | $0.65B | $1.92B | 0.34 |
| 1996-04-30 | $0.71B | $1.79B | 0.40 |
| 1996-01-31 | $0.58B | $1.66B | 0.35 |
| 1995-10-31 | $0.57B | $1.51B | 0.38 |
| 1995-07-31 | $0.60B | $1.43B | 0.42 |
| 1995-04-30 | $0.61B | $1.34B | 0.46 |
| 1995-01-31 | $0.51B | $1.20B | 0.43 |
| 1994-10-31 | $0.52B | $1.14B | 0.46 |
| 1994-07-31 | $0.55B | $1.06B | 0.52 |
| 1994-04-30 | $0.57B | $1.05B | 0.54 |
| 1994-01-31 | $0.40B | $0.92B | 0.43 |
| 1993-10-31 | $0.36B | $0.87B | 0.42 |
| 1993-07-31 | $0.39B | $0.84B | 0.46 |
| 1993-04-30 | $0.45B | $0.84B | 0.54 |
| 1993-01-31 | $0.40B | $0.91B | 0.44 |
| 1992-10-31 | $0.39B | $0.88B | 0.44 |
| 1992-07-31 | $0.33B | $0.85B | 0.39 |
| 1992-04-30 | $0.37B | $0.80B | 0.46 |
| 1992-01-31 | $0.34B | $0.78B | 0.43 |
| 1991-10-31 | $0.32B | $0.74B | 0.43 |
| 1991-07-31 | $0.31B | $0.71B | 0.43 |
| 1991-04-30 | $0.34B | $0.68B | 0.50 |
| 1991-01-31 | $0.32B | $0.65B | 0.49 |
| 1990-10-31 | $0.34B | $0.62B | 0.54 |
| 1990-07-31 | $0.32B | $0.57B | 0.56 |
| 1990-04-30 | $0.32B | $0.57B | 0.57 |
| 1990-01-31 | $0.29B | $0.53B | 0.55 |
| 1989-10-31 | $0.28B | $0.52B | 0.54 |
| 1989-07-31 | $0.27B | $0.50B | 0.54 |
| 1989-04-30 | $0.29B | $0.47B | 0.60 |
| 1989-01-31 | $0.26B | $0.45B | 0.57 |
| 1988-10-31 | $0.25B | $0.43B | 0.59 |
| 1988-07-31 | $0.29B | $0.42B | 0.70 |
| 1988-04-30 | $0.25B | $0.40B | 0.62 |
| 1988-01-31 | $0.20B | $0.38B | 0.55 |
| 1987-10-31 | $0.19B | $0.39B | 0.49 |
| 1987-07-31 | $0.18B | $0.40B | 0.44 |
| 1987-04-30 | $0.17B | $0.39B | 0.45 |
| 1986-04-30 | $0.18B | $0.35B | 0.51 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Products Manufacturing | $129.330B | $33.537B |
| Medtronic, Inc. acquired Ireland-based Covidien plc. The acquisition resulted in the formation of a new holding company incorporated in Ireland - Medtronic plc. The company currently generates revenues from four major segments - namely Cardiovascular Portfolio, Medical Surgical Portfolio, Neuroscience Portfolio and Diabetes. The Cardiovascular Portfolio, formerly reported as the Cardiac and Vascular Group, includes the Cardiac Rhythm & Heart Failure, Structural Heart & Aortic and Coronary & Peripheral Vascular divisions. The Medical Surgical Portfolio, formerly reported as the Minimally Invasive Therapies Group, includes the Surgical Innovations and the Respiratory, Gastrointestinal & Renal divisions. Neuroscience consists of Cranial & Spinal Technologies, Specialty The Neuroscience Portfolio, formerly reported as the Restorative Therapies Group, includes the Cranial & Spinal Technologies, Specialty Therapies, and Neuromodulation divisions. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Abbott Laboratories (ABT) | United States | $186.790B | 20.86 |
| EssilorLuxottica (ESLOY) | France | $145.149B | 0.00 |
| Boston Scientific (BSX) | United States | $137.141B | 31.36 |
| Stryker (SYK) | United States | $135.776B | 26.96 |
| Medline (MDLN) | United States | $60.431B | 0.00 |
| Lonza Group Ag (LZAGY) | Switzerland | $49.968B | 0.00 |
| Agilent Technologies (A) | United States | $38.287B | 24.20 |
| ResMed (RMD) | United States | $36.833B | 25.49 |
| GE HealthCare Technologies (GEHC) | United States | $36.337B | 17.38 |
| Koninklijke Philips (PHG) | Netherlands | $28.310B | 18.49 |
| Terumo (TRUMY) | Japan | $20.239B | 22.78 |
| Insulet (PODD) | United States | $19.106B | 59.30 |
| Zimmer Biomet Holdings (ZBH) | United States | $17.163B | 10.70 |
| Smith & Nephew SNATS (SNN) | United Kingdom | $14.153B | 0.00 |
| Baxter (BAX) | United States | $10.199B | 8.23 |
| Sunny Optical Technology (SNPTF) | China | $8.485B | 0.00 |
| Bio-Rad Laboratories (BIO) | United States | $8.000B | 28.77 |
| Demant (WILYY) | Denmark | $7.372B | 0.00 |
| Lantheus Holdings (LNTH) | United States | $4.477B | 13.64 |
| BillionToOne (BLLN) | United States | $4.008B | 0.00 |
| Envista Holdings (NVST) | United States | $3.920B | 22.49 |
| ICU Medical (ICUI) | United States | $3.769B | 23.93 |
| Haemonetics (HAE) | United States | $3.221B | 14.34 |
| Prestige Consumer Healthcare (PBH) | United States | $3.164B | 14.43 |
| Shandong Weigao Medical Polymer (SHWGF) | China | $3.099B | 0.00 |
| Neogen (NEOG) | United States | $2.132B | 46.67 |
| Perrigo (PRGO) | Ireland | $2.026B | 5.08 |
| AtriCure (ATRC) | United States | $1.942B | 0.00 |
| LeMaitre Vascular (LMAT) | United States | $1.911B | 38.46 |
| QuidelOrtho (QDEL) | United States | $1.908B | 12.27 |
| Curaleaf Holdings (CURLF) | Canada | $1.839B | 0.00 |
| Green Thumb Industries (GTBIF) | United States | $1.672B | 73.27 |
| Phibro Animal Health (PAHC) | United States | $1.581B | 15.79 |
| Kestra Medical Technologies (KMTS) | United States | $1.435B | 0.00 |
| AdaptHealth (AHCO) | United States | $1.366B | 19.78 |
| Lumexa Imaging Holdings (LMRI) | United States | $1.362B | 0.00 |
| BioLife Solutions (BLFS) | United States | $1.197B | 355.29 |
| Capricor Therapeutics (CAPR) | United States | $1.061B | 0.00 |
| Tilray Brands (TLRY) | Canada | $1.054B | 0.00 |
| Maravai LifeSciences Holdings (MRVI) | United States | $0.949B | 0.00 |
| InMode (INMD) | Israel | $0.882B | 9.96 |
| Omeros (OMER) | United States | $0.846B | 0.00 |
| Valneva SE (VALN) | France | $0.841B | 0.00 |
| CeriBell (CBLL) | United States | $0.828B | 0.00 |
| VAREX IMAGING (VREX) | United States | $0.581B | 15.74 |
| Verano Holdings (VRNO) | United States | $0.519B | 0.00 |
| Cerus (CERS) | United States | $0.478B | 0.00 |
| Brainsway (BWAY) | Israel | $0.451B | 76.80 |
| Cresco Labs (CRLBF) | United States | $0.447B | 0.00 |
| Canopy Growth (CGC) | Canada | $0.438B | 0.00 |
| Evolus (EOLS) | United States | $0.319B | 0.00 |
| SEMPERIT AG HLD (SEIGY) | Austria | $0.309B | 0.00 |
| Quanterix (QTRX) | United States | $0.303B | 0.00 |
| Viemed Healthcare (VMD) | United States | $0.278B | 22.18 |
| TriSalus Life Sciences (TLSI) | United States | $0.272B | 0.00 |
| Aurora Cannabis (ACB) | Canada | $0.251B | 147.67 |
| TerrAscend (TSNDF) | Canada | $0.243B | 0.00 |
| Sanuwave Health (SNWV) | United States | $0.228B | 0.00 |
| Organigram Global (OGI) | Canada | $0.224B | 0.00 |
| High Tide (HITI) | Canada | $0.223B | 0.00 |
| Owens & Minor (OMI) | United States | $0.217B | 2.17 |
| Utah Medical Products (UTMD) | United States | $0.196B | 17.30 |
| Sanara MedTech (SMTI) | United States | $0.194B | 0.00 |
| OraSure Technologies (OSUR) | United States | $0.192B | 0.00 |
| Vireo Growth (VREOF) | United States | $0.182B | 0.00 |
| Accendra Health (ACH) | United States | $0.163B | 1.64 |
| Quipt Home Medical (QIPT) | United States | $0.158B | 0.00 |
| Apyx Medical (APYX) | United States | $0.152B | 0.00 |
| FitLife Brands (FTLF) | United States | $0.148B | 0.00 |
| Oramed Pharmaceuticals (ORMP) | United States | $0.135B | 0.00 |
| Jushi Holdings (JUSHF) | United States | $0.118B | 0.00 |
| Fonar (FONR) | United States | $0.115B | 16.77 |
| MacroGenics (MGNX) | United States | $0.114B | 0.00 |
| Exagen (XGN) | United States | $0.104B | 0.00 |
| Biote (BTMD) | United States | $0.101B | 4.42 |
| Sharps Technology (STSS) | United States | $0.063B | 0.00 |
| ImmuCell (ICCC) | United States | $0.057B | 24.08 |
| Nephros (NEPH) | United States | $0.050B | 36.00 |
| Rockwell Medical (RMTI) | United States | $0.045B | 0.00 |
| Veru (VERU) | United States | $0.045B | 0.00 |
| Cytosorbents (CTSO) | United States | $0.043B | 0.00 |
| Modular Medical (MODD) | United States | $0.036B | 0.00 |
| Bonk (BNKK) | United States | $0.032B | 0.00 |
| United-Guardian (UG) | United States | $0.030B | 15.10 |
| Jin Medical (ZJYL) | China | $0.021B | 0.00 |
| Allurion Technologies (ALUR) | United States | $0.016B | 0.00 |
| Cellectar Biosciences (CLRB) | United States | $0.016B | 0.00 |
| INLIF (INLF) | China | $0.008B | 0.00 |
| Innovative Eyewear (LUCY) | United States | $0.007B | 0.00 |
| IM Cannabis (IMCC) | Canada | $0.007B | 0.00 |
| Flora Growth (FLGC) | United States | $0.007B | 0.00 |
| Agape ATP (ATPC) | $0.004B | 0.00 | |
| Zynex (ZYXI) | United States | $0.004B | 0.00 |
| Functional Brands (MEHA) | United States | $0.004B | 0.00 |
| GlucoTrack (GCTK) | United States | $0.003B | 0.00 |
| Meihua Medical Technologies (MHUA) | China | $0.002B | 0.00 |
| Akanda (AKAN) | Canada | $0.000B | 0.00 |
| InterCure (INCR) | Israel | $0.000B | 0.00 |
| InVivo Therapeutics Holdings (NVIVQ) | United States | $0.000B | 0.00 |
| SNDL (SNDL) | Canada | $0.000B | 0.00 |
| Trinity Biotech (TRIB) | Ireland | $0.000B | 0.00 |